6896 (6896) Fair Value & Analysis

Healthcare · Market cap HK$2.3B

6 6896 6896 · HK

PriceHK$3.11

Fair ValueHK$7.30

Upside+134.7%

Quality58/100

Watch 6896 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$4.65 – HK$9.19

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +1.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.75 – HK$4.51 · fair‑value band HK$4.65 – HK$9.19 · the HK$3.11 price screens below the HK$7.30 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6896 (6896) currently trades at HK$3.11, while our model-based Fair Value estimate is HK$7.30 — implying the stock looks roughly 134.7% undervalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6896 generated revenue of HK$943M at a net margin of 26.6%. Revenue declined 5.5% year over year. It earns a return on equity of 17.7%. The balance sheet holds a net cash position of HK$473M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$943M

Revenue growth (YoY) -5.5%

Net margin 26.6%

Return on equity 17.7%

Free cash flow HK$78.0M FY2025

P/E ratio 7.8

More key figures

Operating margin 35.8%

EPS (TTM) HK$0.1100

Dividend yield 10.1%

EPS growth (YoY) -9.2%

Net cash HK$473M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6896 reported revenue of HK$943M in FY2025 versus HK$821M in FY2021, a compound +3.5%/yr. Reported net income was HK$251M in FY2025, compounding +7.6%/yr from FY2021.

Revenue +3.5%/yr

FY21 HK$821M

FY22 HK$992M

FY23 HK$961M

FY24 HK$1.2B

FY25 HK$943M

Net income +7.6%/yr

FY21 HK$188M

FY22 HK$281M

FY23 HK$250M

FY24 HK$319M

FY25 HK$251M

Is 6896 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6896 (6896) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$7.30 versus a price of HK$3.11 — about +135% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 6896?

Our model-based fair value for 6896 is HK$7.30 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.11.

What is the quality score of 6896?

6896 has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6896 (6896)?

6896 reported trailing-twelve-month revenue of about HK$943M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6896?

The net profit margin of 6896 is about 26.6%, meaning it keeps roughly 26.6% of revenue as net income. Based on the latest reported figures.

Does 6896 pay a dividend?

6896 currently shows a dividend yield of about 10.13% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.